EIF4A1 and acute myeloid leukemia: In both AML models, eIF4Ai pre-treatment synergized with Ara-C or FLT3i, expanding to primary AML mouse models the enhanced the cytotoxic effects of eIF4Ai and chemotherapy previously observed in hAML cell lines55; yet, BMSCs increased AML cell survival after combination therapy (Figures 6J and 6K).